CLINICAL TRIAL PHASE IIIb to evaluate predictors of response to linaclotide in patients with irritable bowel syndrome and explore the impact on intestinal symptoms

Next Previous
Trial Profile

CLINICAL TRIAL PHASE IIIb to evaluate predictors of response to linaclotide in patients with irritable bowel syndrome and explore the impact on intestinal symptoms

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Almirall S.A.

    • Most Recent Events

    • 09 May 2017 Results presented at the Digestive Disease Week 2017
    • 09 May 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the Digestive Disease Week 2017
    • 11 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top